Endocyte, Inc. (NASDAQ:ECYT) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Endocyte, Inc. (NASDAQ:ECYT) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.03, Briefing.com reports. Endocyte had a negative return on equity of 29.67% and a negative net margin of 59,808.57%. The firm had revenue of $0.01 million for the quarter. During the same quarter last year, the business earned ($0.25) earnings per share.
Endocyte (ECYT) remained flat at $1.35 during midday trading on Thursday. The stock had a trading volume of 206,011 shares. Endocyte has a 52 week low of $1.32 and a 52 week high of $3.49. The company’s 50-day moving average is $1.46 and its 200-day moving average is $2.05. The stock’s market capitalization is $57.33 million.
ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/endocyte-inc-nasdaqecyt-issues-quarterly-earnings-results-misses-expectations-by-0-03-eps/1468902.html.
Several equities research analysts recently issued reports on ECYT shares. Wedbush reaffirmed an “outperform” rating on shares of Endocyte in a research note on Thursday, May 11th. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. Cowen and Company downgraded shares of Endocyte from an “outperform” rating to a “market perform” rating in a research note on Friday, June 2nd. Finally, ValuEngine downgraded shares of Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Endocyte has an average rating of “Hold” and a consensus target price of $3.58.
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.